Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), along with putative minor metabolites and several deuterium-labeled derivatives. Psilocybin, psilocin, psilocin-O-glucuronide, and 4-HIAA were assayed for engagement at seven serotonin receptor subtypes using a BRET-based binding assay, which showed that only psilocin exhibited any discernible binding across the subtypes investigated. Given the high cost and challenging preparation of these compounds, our work offers a comprehensive guide for researchers to access these resources, advancing both basic and clinical research with psilocybin and its metabolites.
Authors
- Rachel Friedman Ohana (ORCID: https://orcid.org/0000-0001-6706-4592)
- Alexander M. Sherwood (ORCID: https://orcid.org/0000-0003-0895-0791)
- Ilia A. Guzei (ORCID: https://orcid.org/0000-0003-1976-7386)
- James J. Cali
- Mike Valley
- Elise K. Burkhartzmeyer
- Michael T. Faley
- Samuel E. Williamson (ORCID: https://orcid.org/0009-0002-0108-8764)
Institutions
- University of Wisconsin–Madison (US)
- MRC Laboratory of Molecular Biology (GB)
- Promega (United States) (US)
- Laboratory of Molecular Genetics (PL)
- Usona Institute (US)
Publication Details
- Journal
- ACS Chemical Neuroscience
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1021/acschemneuro.5c00879
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00